2020
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMedian overall survivalTherapy-related malignanciesOverall survivalMyelodysplastic syndromeMyeloid leukemiaAllogeneic hematopoietic stem cell transplantLonger median overall survivalSingle-center retrospective studyComplex karyotypeHematopoietic stem cell transplantIntensive chemotherapy approachesYale Cancer CenterCharacteristics of patientsSingle-center experienceMinority of patientsStem cell transplantLong-term survivalLow response rateIntensive chemotherapyCenter experienceClinicopathologic characteristicsAdverse prognosisAML patientsCell transplant
2018
Hematopoietic Stem Cell Donor Selection and Graft-Versus-Host Disease
Siddon A, Tormey C. Hematopoietic Stem Cell Donor Selection and Graft-Versus-Host Disease. 2018, 105-117. DOI: 10.1007/978-3-319-89866-7_7.ChaptersCell transplantSide effectsHematopoietic progenitor cell transplantStem cell transplantMalignant hematological diseasesProgenitor cell transplantPotential side effectsStem cell sourceGraft-VersusHPC transplantHost diseaseABO compatibilityPotential complicationsDonor selectionHematological diseasesApheresis servicesPossible treatmentTransplantSevere disordersCell sourceDiseaseManagement optionsComplicationsPatientsTransplantation